...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: BETonMACE Enrollment
7
Mar 21, 2017 04:22PM
7
Mar 24, 2017 03:15PM
3
Mar 24, 2017 03:34PM
2
Mar 25, 2017 10:41AM
4
Mar 25, 2017 11:14AM
2
Mar 25, 2017 02:27PM
5
Mar 25, 2017 04:07PM
6
Mar 26, 2017 03:01PM
3
Mar 28, 2017 03:07PM
3
Mar 28, 2017 03:26PM
2
Mar 28, 2017 03:39PM
4
Jun 28, 2017 10:37AM
6
Aug 28, 2017 12:56PM
3
Aug 28, 2017 01:57PM
1
Aug 28, 2017 02:16PM
2
Aug 28, 2017 03:09PM
3
Aug 28, 2017 10:05PM
6
Aug 29, 2017 08:00AM
4
Aug 29, 2017 09:29AM
6
Aug 30, 2017 06:18PM
3
Aug 30, 2017 07:30PM
3
Aug 30, 2017 08:17PM
15
Sep 02, 2017 12:03PM
2
Sep 02, 2017 12:45PM
3
Sep 02, 2017 02:06PM
3
Sep 02, 2017 02:21PM
5
Dec 14, 2017 04:51PM
3
Dec 15, 2017 12:32AM
7
Dec 15, 2017 11:40AM
4
Dec 15, 2017 01:00PM
2
Dec 15, 2017 02:25PM
4
Dec 15, 2017 07:33PM
3
Jan 11, 2018 02:40PM
6
Jan 11, 2018 03:01PM
3
Jan 11, 2018 03:29PM
2
Feb 28, 2018 03:21PM
7
Mar 01, 2018 11:38AM
1
Mar 01, 2018 02:17PM
4
Feb 08, 2019 10:07AM
2
Feb 08, 2019 04:50PM
4
Feb 08, 2019 11:03PM
1
Feb 09, 2019 02:43PM

Feb 09, 2019 03:31PM
3
Feb 09, 2019 03:52PM

Feb 09, 2019 04:14PM
1
Feb 09, 2019 08:00PM
2
Feb 09, 2019 09:12PM
2
Feb 10, 2019 12:33PM
1
Feb 11, 2019 09:05AM
1
Feb 22, 2019 04:10PM
3
Feb 22, 2019 05:31PM

"It's not a stretch at all. BD1 and BD2 serve complementary functions. By inhibiting one, you are still able to inhibit the combined function."

Pomp, to me it sounds like you are implying that inhibitting BD1 and/or BD2 all elicit the same effect on the BET protein and biological outcome. This is not true. Even the paper you cite argues against your proposal:

"Collectively, our results suggest that selective inhibition of the first BrD (such as by Olinone or MS611) facilitates the progression of primary oligodendrocyte progenitors toward a differentiated phenotype, inhibition of the second BrD (such as by MS765/RVX-208) has no effect, and inhibition of both BrDs of BET proteins (such as MS417) negatively affects the differentiation process"

Not all BD-2 selective BET inhibitors are created equal. Not all BD-1 selective BET inhibitors are created equal. Not all pan-BET inhibitors are created equal. Different inhibitors can have different structures, bind to different regions of the bromodomain acetyl-lysine binding pocket, elicit different conformational shifts in the bromodomain, have different pharmacokinetics, different tissue distribution, have different affinities for BD2 vs. BD1, and cause different gene expression changes.

Of course, some of this is concentration dependent. At a high enough concentration, even a BD2 selective BET inhibitor will bind and robustly inhibit BD1, and vice versa. But at optimal concentrations, there is still BD selectivity for BD-selective inhibitors. Pan-BET inhibitors have been extensively studies for oncology and come with significant toxicity issues. If BD2 inhibition compromises BD1 function, or vice versa, one would predict that BD-selective inhibitors would act the same as pan-BET inhibitors. This has been shown in numerous studies to not be the case. Why would Resverlogix and Zenith tout their extensive compound libraries with different bromodomain selectivities if this didn't matter?

See this post on bromodomain vs BET protein selectivity. See this post on RVX-297. See this post on ABBV-744. 

BearDownAZ

5
Feb 23, 2019 02:33PM
1
Aug 18, 2019 10:29AM
5
Aug 18, 2019 01:02PM
3
Aug 18, 2019 01:47PM
2
Aug 18, 2019 01:57PM
3
Aug 18, 2019 02:26PM
3
Aug 18, 2019 02:28PM
3
Aug 18, 2019 04:41PM
2
Aug 18, 2019 04:59PM
3
Aug 18, 2019 06:54PM
3
Aug 18, 2019 07:04PM
4
Aug 18, 2019 08:24PM
Share
New Message
Please login to post a reply